Trial Profile
A Prospective, Single Product, Observational Registry Involving Patients Presenting With Locally Advanced or Metastatic Prostate Cancer Receiving Eligard as Androgen Deprivation Treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2016
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 21 Dec 2016 Status changed from active, no longer recruiting to completed.
- 31 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Oct 2009 New trial record